Kaneka Of Japan To Buy Majority Of Eurogentec For Biopharma Entry
This article was originally published in PharmAsia News
Japan's Kaneka, a contract manufacturer of pharmaceuticals, said it intends to buy a majority share of Belgium's Eurogentec, maker of biologics for biopharmaceuticals, for about $44 million
You may also be interested in...
The US company is bringing extra supplies of lopinavir/ritonavir into France but stresses that the combination treatment is not authorized for treating patients with the coronavirus.
GSK commits to investing behind OTC and oral health brands in India after offloading nutrition assets to Unilever.
The Belgian biotech has managed to attract considerable sums from venture capitalists over the past couple of years amid hopes that its two next-generation immunotherapies will be best-in-class agents.